Figures & data
Figure 1 Flow chart from inclusion to 2 years.
Table 1 Change in Mean Best Corrected Visual Acuity, CMT and VM Relative to Baseline
Table 2 Number and Interval of Aflibercept Intravitreal Injection in DME Vitrectomized Eyes
Clinical Ophthalmology
Volume 16, 2022 - Issue
Original Research
Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
Thi Ha Chau Tran1 Ophthalmology Department, Lille Catholic Hospitals, Lille Catholic University, INSERM, U1172, Lille, FranceCorrespondence[email protected]
https://orcid.org/0000-0001-9066-7092View further author information
https://orcid.org/0000-0001-9066-7092View further author information, Stephane Verdun2 Biostatistics Department-Delegations for Clinical Research and Innovation, Lille Catholic Hospitals, Lille, Francehttps://orcid.org/0000-0002-1381-3540View further author information
https://orcid.org/0000-0002-1381-3540View further author information, , Joel Uzzan4 Clinique Mathilde, Rouen, Francehttps://orcid.org/0000-0001-6686-4854View further author information
https://orcid.org/0000-0001-6686-4854View further author information, , Laurent Kodjikian6 Ophthalmology Department, Hospice Civils de Lyon, Lyon 1 University, UMR-CNRS 5510, Lyon, Francehttps://orcid.org/0000-0002-3908-6716View further author information
https://orcid.org/0000-0002-3908-6716View further author information & Ali Erginay7 Ophthalmology Department, Lariboisière Hospital, Paris University, Paris, Francehttps://orcid.org/0000-0003-1960-3437View further author information
https://orcid.org/0000-0003-1960-3437View further author information show all